Janux Therapeutics

Last year was far from vintage for the biotech sector in terms of stock performance: the S&P Biotechnology Select Industry Index rose by only 3% in 2024, and lagged far behind the 25% achieved by

Vir Biotechnology’s move from focusing solely on antiviral drugs to incorporating oncology into its pipeline has shown early signs of potentially paying off as the company announced safety and efficac

Many public biopharmaceutical companies have taken advantage of the ongoing capital markets recovery in 2024 by raising money through follow-on public offerings (FOPOs) after announcing key research a

Janux Therapeutics has generated great excitement with its prostate cancer treatment, JANX007, with analysts hailing updated Phase I results as showing potential best-in-class safety and efficacy. Li